Cardiovascular Drugs Practice Questions

Q: Which of the following is the most effective medication for reducing proteinuria in diabetic patients?

Perindopril. ***Perindopril*** - **Perindopril** is an **ACE inhibitor**, which are cornerstone drugs for reducing **proteinuria** in diabetic patients by lowering intraglomerular pressure and reducing glomerular hyperfiltration. - ACE inhibitors like perindopril have been shown to slow the progression of **diabetic nephropathy** and improve renal outcomes beyond just their antihypertensive effects. *Chlorthalidone* - **Chlorthalidone** is a **thiazide-type diuretic** primarily used for hypertension management and edema. - While it lowers blood pressure, it does not have the specific renoprotective effects on **proteinuria** that ACE inhibitors possess in diabetic nephropathy. *Clonidine* - **Clonidine** is a **central alpha-2 adrenergic agonist** used for hypertension, but it does not specifically target the mechanisms of proteinuria. - It works by reducing sympathetic outflow from the central nervous system, which is distinct from the renal hemodynamic effects of ACE inhibitors. *Metoprolol* - **Metoprolol** is a **beta-blocker** primarily used for hypertension and cardiovascular conditions. - While it reduces blood pressure, it does not offer the same degree of proteinuria reduction or renoprotective benefits in diabetic nephropathy as ACE inhibitors.

Q: In a patient diagnosed with pheochromocytoma, what is the appropriate preoperative pharmacological management to control hypertension before surgery?

Phenoxybenzamine and propranolol. ***Phenoxybenzamine and propranolol*** - **Phenoxybenzamine** (an **irreversible** non-selective **alpha-blocker**) is initiated first to prevent hypertensive crises during surgery by blocking the effects of catecholamines on blood vessels. - **Propranolol** (a **beta-blocker**) is added after adequate alpha-blockade to control **tachycardia** and arrhythmias, as blocking only alpha-receptors can lead to unopposed beta-adrenergic stimulation. *Phentolamine (short-acting alpha blocker)* - While **phentolamine** is an alpha-blocker, it is typically used for **intraoperative management** of hypertensive crises or for short-term control, not as the primary preoperative preparation. - It is a **reversible** blocker and does not provide the sustained, robust alpha-blockade required for safe preoperative management of pheochromocytoma. *Propranolol (beta-blocker)* - **Beta-blockers** alone should **never be started first** in pheochromocytoma because blocking beta-2 receptors (which mediate vasodilation) in the presence of high circulating catecholamines can lead to **unopposed alpha-adrenergic vasoconstriction**, causing a dangerous hypertensive crisis. - It is only added after adequate alpha-blockade has been achieved to manage **tachycardia**. *Nitroglycerine (vasodilator)* - **Nitroglycerine** is primarily a **venodilator** and is used to relieve angina or manage acute hypertensive emergencies, not for the chronic preoperative management of pheochromocytoma. - It does not address the underlying pathophysiology of excessive catecholamine release and can lead to reflex **tachycardia**.

Q: All drugs decrease mortality in heart failure except:

Digoxin. ***Digoxin*** - **Digoxin** is known to improve symptoms and reduce hospitalizations in heart failure, but it has **not been shown to decrease mortality** in large clinical trials (DIG trial). - Its narrow **therapeutic window** and potential for toxicity, especially in patients with renal impairment, limit its use primarily to symptom management. *Metoprolol* - **Metoprolol succinate**, a beta-blocker, significantly reduces mortality and morbidity in patients with chronic heart failure with reduced ejection fraction (MERIT-HF trial) by blocking the deleterious effects of the sympathetic nervous system. - It works by reducing heart rate, myocardial oxygen demand, and cardiac remodeling. *Enalapril* - **Enalapril**, an ACE inhibitor, is a cornerstone medication in heart failure treatment due to its proven ability to reduce mortality, hospitalizations, and improve quality of life (CONSENSUS, SOLVD trials). - It works by blocking the **renin-angiotensin-aldosterone system**, leading to vasodilation, reduced preload and afterload, and prevention of cardiac remodeling. *Telmisartan* - **Telmisartan**, an ARB (angiotensin receptor blocker), is used as an alternative in heart failure patients who cannot tolerate ACE inhibitors due to side effects like cough. - ARBs as a class have shown mortality benefits in heart failure, acting by blocking the **angiotensin II type 1 receptor**, producing similar cardiovascular benefits to ACE inhibitors in terms of vasodilation and reduction in cardiac remodeling.

Q: In a diabetic patient with hypertension, which of the following medications is the most suitable choice for management?

Enalapril. ***Enalapril*** - **ACE inhibitors** like enalapril are first-line agents in diabetic patients with hypertension due to their **renoprotective effects**, slowing the progression of **diabetic nephropathy**. - They reduce **glomerular pressure** and **albuminuria**, which is crucial in managing long-term complications of diabetes. *Propranolol* - **Beta-blockers** like propranolol can mask symptoms of **hypoglycemia** (e.g., tremors, palpitations), which is a significant concern in diabetic patients. - They may also worsen **insulin resistance** and negatively impact the lipid profile. *Clonidine* - **Clonidine**, an alpha-2 agonist, is typically reserved for **resistant hypertension** or specific conditions like **ADHD** due to its side effects. - It can cause significant **sedation**, **dry mouth**, and **rebound hypertension** upon sudden discontinuation, making it less suitable for routine management. *Hydrochlorothiazide* - **Thiazide diuretics** can cause adverse metabolic effects in diabetic patients, including **hyperglycemia** and worsening of **insulin resistance**. - While effective for hypertension, their metabolic profile makes them less preferred as a first-line agent in patients with diabetes.

Q: Which of the following drugs lack vasodilatory properties but are effective in angina?

Metoprolol. ***Metoprolol*** - **Metoprolol** is a beta-blocker that reduces myocardial oxygen demand by decreasing heart rate, contractility, and blood pressure, without direct vasodilatory effects. - Its efficacy in angina is primarily due to these **cardiac depressant actions**, which relieve myocardial ischemia. *Isosorbide dinitrate* - **Isosorbide dinitrate** is a nitrate that works by releasing nitric oxide, leading to **venodilation** and **arterial dilation**, particularly reducing preload and improving coronary blood flow. - Its anti-anginal effect is directly linked to its **vasodilatory properties**. *Nifedipine* - **Nifedipine** is a dihydropyridine calcium channel blocker that produces potent **vasodilation** of both coronary and peripheral arteries. - Its primary mechanism of action in angina involves **reducing afterload** and improving coronary blood flow through vasodilation. *Verapamil* - **Verapamil** is a non-dihydropyridine calcium channel blocker that causes **coronary and peripheral vasodilation**, reducing afterload and improving myocardial perfusion. - While it also reduces heart rate and contractility, its direct **vasodilatory effects** contribute significantly to its anti-anginal action.

Q: Which of the following enzymes is not targeted by hypolipidemic drugs?

Peripheral decarboxylase. ***Peripheral decarboxylase*** - **Peripheral decarboxylase** (also known as DOPA decarboxylase) is involved in the synthesis of dopamine from L-DOPA and is a target for drugs used in **Parkinson's disease**, not hypolipidemic drugs. - Its inhibition by drugs like **carbidopa** or **benserazide** prevents the peripheral conversion of L-DOPA to dopamine, increasing L-DOPA availability for the brain. *HMG Co A reductase* - **HMG-CoA reductase** is the rate-limiting enzyme in cholesterol biosynthesis and is the primary target for **statins** (e.g., atorvastatin, simvastatin). - Statins effectively lower **LDL cholesterol** by inhibiting this enzyme, reducing endogenous cholesterol production. *Lipoprotein lipase* - **Lipoprotein lipase (LPL)** activity can be enhanced by certain hypolipidemic drugs, such as **fibrates**, which activate **PPAR-α**. - Increased LPL activity leads to enhanced hydrolysis of **triglycerides** from VLDL and chylomicrons, reducing triglyceride levels in plasma. *Acyl CoA, cholesterol acyl transferase 1* - **Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors** were developed as potential hypolipidemic agents to prevent cholesterol esterification and absorption. - While not widely used clinically due to efficacy and side effect profiles, **ACAT1** is involved in cholesterol esterification in the intestine and liver, making it a target for reducing cholesterol absorption.

Q: Which calcium channel blocker is known to cause reflex tachycardia?

Nifedipine. ***Nifedipine*** - **Nifedipine** is a **dihydropyridine calcium channel blocker** that causes significant **peripheral vasodilation**. - This rapid drop in blood pressure activates the **baroreceptor reflex**, leading to an increase in heart rate (**reflex tachycardia**) to compensate. *Verapamil* - **Verapamil** is a **non-dihydropyridine calcium channel blocker** that acts on both vascular smooth muscle and cardiac conduction. - It has a direct negative chronotropic effect on the heart, which typically **prevents reflex tachycardia**. *Amlodipine* - **Amlodipine** is a **long-acting dihydropyridine calcium channel blocker** with a more gradual onset of action. - While it causes peripheral vasodilation, its **slow onset and prolonged duration** of action typically result in less pronounced or absent reflex tachycardia compared to nifedipine. *Diltiazem* - **Diltiazem** is a **non-dihydropyridine calcium channel blocker** with effects on both the heart and peripheral vasculature. - Similar to verapamil, its direct **negative chronotropic and dromotropic effects** on the heart prevent significant reflex tachycardia.

Q: Which drug used for the common cold has been associated with an increased risk of stroke?

Pseudoephedrine. ***Pseudoephedrine*** - Pseudoephedrine is a **sympathomimetic** that can cause **vasoconstriction**, leading to increased blood pressure and heart rate, which elevates the risk of stroke, especially in susceptible individuals [1, 2, 3]. - Its mechanism of action involves stimulating **alpha- and beta-adrenergic receptors**, producing systemic vasoconstriction that reduces nasal congestion [1]. - **FDA restrictions** were placed on pseudoephedrine sales due to well-documented cardiovascular risks, including **hemorrhagic stroke**, particularly in young women and patients with uncontrolled hypertension [3].*Phenylephrine* - Phenylephrine is also a **sympathomimetic decongestant**, primarily an **alpha-1 adrenergic agonist**, causing vasoconstriction [3]. - While it can theoretically increase blood pressure, its **oral bioavailability is poor** (approximately 38%) due to extensive first-pass metabolism, resulting in less consistent systemic effects compared to pseudoephedrine. - The stroke risk association is **significantly lower** than pseudoephedrine, making it a preferred alternative in many guidelines.*Diphenhydramine* - Diphenhydramine is an **antihistamine with anticholinergic properties** used for allergy symptoms and sedation, not primarily as a decongestant. - It does not have a direct mechanism of action that significantly increases the risk of stroke through vasoconstriction. - May cause drowsiness and anticholinergic side effects, but not associated with acute cardiovascular events like stroke.*Oxymetazoline* - Oxymetazoline is a **topical decongestant** found in nasal sprays, which acts as a direct **alpha-adrenergic agonist**. - While it causes local vasoconstriction, systemic absorption is **minimal with topical use**, and it is less associated with stroke risk compared to oral decongestants like pseudoephedrine. - Main concern is **rebound congestion** (rhinitis medicamentosa) with prolonged use, not cardiovascular events.

Q: Which of the following drugs has the LEAST cardiac side effects when used for treating an acute attack of asthma in a cardiovascular patient?

Ipratropium (short-acting anticholinergic). ***Ipratropium (short-acting anticholinergic)*** - Ipratropium is a **bronchodilator** that acts as an **anticholinergic** via **M3 muscarinic receptor antagonism** in the airways. - It has **minimal systemic absorption** and produces **no direct cardiac stimulation**, making it the option with the least cardiovascular side effects. - While typically used as an **adjunct to beta-agonists** in acute asthma, it has the most favorable cardiac safety profile among bronchodilators. - Particularly useful in patients with **severe cardiovascular disease** where minimizing cardiac stimulation is crucial. *Salbutamol (short-acting beta-agonist)* - Salbutamol is a **selective beta-2 adrenergic agonist** and the first-line treatment for acute asthma. - Despite beta-2 selectivity, it can have **off-target effects on cardiac beta-1 receptors**, potentially causing tachycardia, palpitations, and increased myocardial oxygen demand. - At therapeutic doses, cardiac effects are usually mild and acceptable even in cardiovascular patients, but more pronounced than ipratropium. *Terbutaline (short-acting beta-agonist)* - Terbutaline is a **beta-2 agonist** with similar cardiac risk profile to salbutamol. - Can cause **tachycardia and arrhythmias** due to non-specific beta-adrenergic activation, particularly at higher doses or in sensitive patients. - Effective for acute bronchodilation but produces more cardiac stimulation than anticholinergics. *Formoterol (long-acting beta-agonist)* - Formoterol is a **long-acting beta-2 agonist (LABA)** with rapid onset but prolonged duration of action. - **Not recommended for acute asthma attacks** as monotherapy; LABAs are maintenance medications. - Has potential for significant **cardiac side effects** including palpitations, tremor, and arrhythmias due to prolonged beta-adrenergic stimulation. - Carries greater cardiovascular risk than short-acting agents due to extended systemic exposure.

Q: Which of the following alpha-blocker drugs is used in the treatment of benign prostatic hyperplasia without producing significant hypotension?

Tamsulosin. ***Tamsulosin*** - Tamsulosin is a **selective alpha-1a adrenergic receptor blocker**, which primarily targets receptors in the **prostate** and bladder neck. - Its selectivity minimizes effects on vascular alpha-1b receptors, thereby *reducing the incidence of orthostatic hypotension* compared to non-selective alpha-blockers. *Doxazosin* - Doxazosin is a **non-selective alpha-1 blocker** that affects both prostatic and vascular smooth muscle, making **hypotension a more common side effect**. - While effective for BPH, it is also used for hypertension, indicating its significant impact on **blood pressure**. *Phentolamine* - Phentolamine is a **non-selective alpha-adrenergic blocker** used in pheochromocytoma and hypertensive crises, but not typically for BPH. - It can cause **significant hypotension** due to its widespread alpha-receptor antagonism. *Terazosin* - Similar to doxazosin, terazosin is a **non-selective alpha-1 blocker** that causes peripheral vasodilation. - This property means it can lead to **symptomatic hypotension**, especially upon initiation of therapy.

Question 1

Which of the following is the most effective medication for reducing proteinuria in diabetic patients?

Accepted Answer

Perindopril

Answer

Clonidine

Answer

Chlorthalidone

Answer

Metoprolol

Question 2

In a patient diagnosed with pheochromocytoma, what is the appropriate preoperative pharmacological management to control hypertension before surgery?

Accepted Answer

Phenoxybenzamine and propranolol

Answer

Propranolol

Answer

Nitroglycerine

Answer

Phentolamine

Question 3

All drugs decrease mortality in heart failure except:

Accepted Answer

Digoxin

Answer

Enalapril

Answer

Metoprolol

Answer

Telmisartan

Question 4

In a diabetic patient with hypertension, which of the following medications is the most suitable choice for management?

Accepted Answer

Enalapril

Answer

Clonidine

Answer

Hydrochlorothiazide

Answer

Propranolol

Question 5

Which of the following drugs lack vasodilatory properties but are effective in angina?

Accepted Answer

Metoprolol

Answer

Isosorbide dinitrate

Answer

Nifedipine

Answer

Verapamil

Question 6

Which of the following enzymes is not targeted by hypolipidemic drugs?

Accepted Answer

Peripheral decarboxylase

Answer

HMG Co A reductase

Answer

Lipoprotein lipase

Answer

Acyl CoA, cholesterol acyl transferase 1

Question 7

Which calcium channel blocker is known to cause reflex tachycardia?

Accepted Answer

Nifedipine

Answer

Verapamil

Answer

Amlodipine

Answer

Diltiazem

Question 8

Which drug used for the common cold has been associated with an increased risk of stroke?

Accepted Answer

Pseudoephedrine

Answer

Diphenhydramine

Answer

Phenylephrine

Answer

Oxymetazoline

Question 9

Which of the following drugs has the LEAST cardiac side effects when used for treating an acute attack of asthma in a cardiovascular patient?

Accepted Answer

Ipratropium (short-acting anticholinergic)

Answer

Salbutamol (short-acting beta-agonist)

Answer

Terbutaline (short-acting beta-agonist)

Answer

Formoterol (long-acting beta-agonist)

Question 10

Which of the following alpha-blocker drugs is used in the treatment of benign prostatic hyperplasia without producing significant hypotension?

Accepted Answer

Tamsulosin

Answer

Doxazosin

Answer

Phentolamine

Answer

Terazosin

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?